Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Philip Morris International : Medicago develops a plant-based vaccine for Coronavirus

03/19/2020 | 12:43pm EST

Medicago has made significant progress toward producing an experimental plant-based vaccine for COVID-19.

The Canada-headquartered biopharmaceutical company is using a virus-like particle (VLP) grown in Nicotiana Benthamiana, a close relative of the tobacco plant, to develop a potential vaccine against the coronavirus disease that has now reached a global pandemic level.

It's an example of how rapidly science and innovation can achieve positive results for society, regardless of who is funding it.

Following its announcement, Medicago, which is part-funded by Philip Morris International (PMI), said it's ready to start preclinical testing for safety and efficacy, anticipating the beginning of human trials later this summer.

Medicago is a leader in proprietary plant-based technology that uses virus-like particles (VLP) to develop protein-based vaccines, instead of relying on animal products or live viruses.

The advantages of VLPs over traditional vaccines

Virus-like particles are used to create plant-based vaccines, which mimic viruses, enabling the body's immune system to recognize them and create an immune response. But they lack the core genetic material of a virus, so they're not infectious and can't replicate.

Medicago's technology only requires the genetic sequence of a viral strain, not the live virus itself. So, the company can mass-produce a therapy to attack a pandemic infection like COVID-19 within a month after health officials identify it.

VLP vs traditional vaccine development

By comparison, traditional vaccine development in chicken eggs takes six to nine months. Vaccine manufacturers inject the virus into the eggs, where it propagates. But using eggs is expensive, takes a long time, and is far from perfect. Mutations can yield vaccines that don't match up to the virus they aim to shut down.

Using a plant-based approach is relatively new, but it has advanced rapidly in the past decade. It inserts a genetic sequence into agrobacterium, a soil-based bacterium, which is taken up by plants - in this case, a close relative of a tobacco plant. The plant begins to produce the protein, that can then be used as a vaccine. If the virus begins to mutate, as is expected for COVID-19, they can update the production using new plants.

Using plants and genetically engineered agrobacteria works faster than eggs, and also makes the vaccine much easier to produce at scale.

Medicago is not new to innovative work on vaccines

In addition to coronavirus treatments, Medicago's pipeline includes other experimental virus and pandemic therapies. Its first product, a seasonal flu vaccine, is currently under review by Health Canada.

The company is also using its technology to develop antibodies against SARS-CoV-2 in collaboration with Laval University's Infectious Disease Research Center. According to recent studies, the antibodies could potentially be used to treat people infected by the coronavirus.

Medicago is partially owned by Philip Morris International, and is part of the company's new course, based on science, technology, and innovation. PMI acquired a stake in Medicago in 2013, and currently holds approximately one third of the company's shares. Japan-based Mitsubishi Tanabe Pharma owns the remaining two thirds.


Philip Morris International Inc. published this content on 19 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 March 2020 17:42:01 UTC

ę Publicnow 2020
01/12CAPITALGAINSREPORT : 'Sin Stocks' Surge In Alcohol, Tobacco And Casinos (LVS, PM, ROAG And..
01/11UBS Adjusts Philip Morris International Price Target to $95 From $90, Maintains Neutral..
01/06Why TAAT Global Alternatives Inc could be a threat to the tobacco industry (TOBAF, PM, ..
2021PMI PARTNERS WITH AFRICAN DATA SCIEN : PMI partners with African data scientists
2021PHILIP MORRIS INTERNATIONAL : PMI partners with African data scientists
2021PHILIP MORRIS INTERNATIONAL, INC. : Ex-dividend day for
2021CARBON-NEUTRAL FACTORIES : Helping deliver PMI's Low-Carbon Transition Plan
2021PHILIP MORRIS INTERNATIONAL : PMI leaders' reflections on 2021, and learnings for 2022
2021What Lies Ahead in 2022?
More news
Analyst Recommendations on PHILIP MORRIS INTERNATIONAL, INC.
More recommendations
Financials (USD)
Sales 2021 31 196 M - -
Net income 2021 9 149 M - -
Net Debt 2021 24 169 M - -
P/E ratio 2021 17,4x
Yield 2021 4,81%
Capitalization 158 B 158 B -
EV / Sales 2021 5,85x
EV / Sales 2022 5,67x
Nbr of Employees 71 000
Free-Float 73,7%
Duration : Period :
Philip Morris International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHILIP MORRIS INTERNATIONAL, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 101,73 $
Average target price 109,49 $
Spread / Average Target 7,63%
EPS Revisions
Managers and Directors
Jacek Olczak Chief Executive Officer & Director
Emmanuel Andre Marie Babeau Chief Financial Officer
AndrÚ Calantzopoulos Executive Chairman
Patrick Brunel Chief Information Officer & Senior Vice President
Bertrand Bonvin Senior Vice President-Research & Development